about
pso@autodock: a fast flexible molecular docking program based on Swarm intelligence.An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.Characterization of P2X4 receptor agonists and antagonists by calcium influx and radioligand binding studies.Interaction of Approved Drugs with Synaptic Vesicle Protein 2A.Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.Skin whitening agents: medicinal chemistry perspective of tyrosinase inhibitors.HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and lead optimization using CoMFA and CoMSIA studies (1995-2016).Role of extracellular cysteine residues in the adenosine A2A receptor.Substrate-Dependence of Competitive Nucleotide Pyrophosphatase/Phosphodiesterase1 (NPP1) Inhibitors.Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y2 Receptor.Development of Potent and Selective Antagonists for the UTP-Activated P2Y4 Receptor.Probing the binding mechanism of mercaptoguanine derivatives as inhibitors of HPPK by docking and molecular dynamics simulations.The promiscuous ectonucleotidase NPP1: molecular insights into substrate binding and hydrolysis.Exploring SAR continuity in the vicinity of activity cliffs.Fluorescent-labeled selective adenosine A2B receptor antagonist enables competition binding assay by flow cytometry.Design, Synthesis, and Characterization of Some Hybridized Pyrazolone Pharmacophore Analogs against Mycobacterium tuberculosis.6-(Ar)Alkylamino-Substituted Uracil Derivatives: Lipid Mimetics with Potent Activity at the Orphan G Protein-Coupled Receptor 84 (GPR84).Development of a selective and highly sensitive fluorescence assay for nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39)Inhibitors of Melanogenesis: An Updated ReviewThe Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR172,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2Agonists and Antagonists for Purinergic ReceptorsRadiosynthesis and in vivo evaluation of a fluorine-18 labeled pyrazine based radioligand for PET imaging of the adenosine A2B receptorAn Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural InsightsSubstituted 4-phenylthiazoles: Development of potent and selective A1, A3 and dual A1/A3 adenosine receptor antagonistsOverview of Recent Strategic Advances in Medicinal ChemistryLigand binding and activation of UTP-activated G protein-coupled P2Y2 and P2Y4 receptors elucidated by mutagenesis, pharmacological and computational studiesA2B Adenosine Receptor Antagonists with Picomolar PotencyCell-permeable high-affinity tracers for Gq proteins provide structural insights, reveal distinct binding kinetics and identify small molecule inhibitorsDesign and synthesis of sulfonamidophenylethylamides as novel cardiac myosin activatorStructure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) InhibitorsIdentification of Thienopyrimidine Scaffold as an Inhibitor of the ABC Transport Protein ABCC1 (MRP1) and Related Transporters Using a Combined Virtual Screening ApproachComputational Investigations on the Binding Mode of Ligands for the Cannabinoid-Activated G Protein-Coupled Receptor GPR18
P50
Q33305123-2F659A31-58B1-4519-9DD8-DED137742ED6Q35923992-A6C407F7-90C0-44F4-89B8-FA33EDD06876Q36198892-3C56CE16-65F3-43CC-9ECB-ECB97B2DDFECQ36285895-FB973E37-BD00-46AD-87A2-DA9A61AC1421Q38830019-3C0582A4-DD24-4F0B-BD32-8B8F9331AFDAQ39093314-E621F434-D3AB-4998-AC16-3EE5CA202B62Q39420325-B5EA7FDE-41FB-44B2-B0F3-DF9B2DFD50E3Q40932261-3E1482C3-2F98-4557-8E43-5F7D9346046AQ42321503-1E2F63D6-C0C5-4DF0-8792-2489B75C4656Q47761844-BE064F9C-ECCA-4A13-9BB5-AE8CBC8A9D12Q48110307-BFF9F534-356D-496B-8BDD-8B065763FEDAQ51100494-65E627FF-E75B-4904-BA6F-821B2C0547C4Q51239629-6F7E8812-CA29-4031-A5FB-BA63030AB7A3Q51523045-357220AD-7173-4232-BC01-793936149831Q52571887-23DD26C8-6AF3-4CFD-BDDC-49771127D587Q54196868-928F065D-52C0-48F9-BB88-F5CB62BC2D3AQ55692244-CDE8E789-FAAA-43CF-BB84-20C437FA724AQ57707843-248EB7F1-5202-4CE0-A265-360F5D176B5DQ61440855-1252B09C-0256-43AE-B010-F98D3E71759BQ90274970-12B35CB2-12F3-4590-8E3D-43F7A9DA8B0EQ90501480-F11270EB-813D-4106-BFFC-97E1D529EA90Q90742973-7319ADD3-11EB-4C75-89B2-753E57E0D105Q90915695-DCF036ED-C9F9-479F-90C5-E8ED8CF83F75Q90925760-EAC77B7D-1392-4EC6-9DBA-4223E35C45A8Q91266910-B2E38F01-4E00-4F81-845A-46271D6DBE81Q91521296-0B03FE94-15B8-4D32-9C94-C509AFEE8E50Q91726150-8A07C9AA-5A97-463B-A6CD-0A338C055519Q91776404-C214ECC8-08AF-40C9-ACF5-D02A8D8ABBC6Q92138858-5BD13384-F937-4BC1-B689-9620E362BD5AQ92278251-9F933AFB-2B26-4177-BBAA-DBA2E97B0C4AQ92396421-F6A2D688-662B-424D-8F95-B1B9CCB11BCEQ92518836-0EFED6A0-A73F-4432-8467-31BFE52D1DF6Q92698535-254E5036-86D0-4A14-83A4-1BA2438DBCBEQ94513872-670ABFD5-C313-4794-81D2-10A0E4642314
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vigneshwaran Namasivayam
@ast
Vigneshwaran Namasivayam
@en
Vigneshwaran Namasivayam
@es
Vigneshwaran Namasivayam
@nl
Vigneshwaran Namasivayam
@sl
type
label
Vigneshwaran Namasivayam
@ast
Vigneshwaran Namasivayam
@en
Vigneshwaran Namasivayam
@es
Vigneshwaran Namasivayam
@nl
Vigneshwaran Namasivayam
@sl
prefLabel
Vigneshwaran Namasivayam
@ast
Vigneshwaran Namasivayam
@en
Vigneshwaran Namasivayam
@es
Vigneshwaran Namasivayam
@nl
Vigneshwaran Namasivayam
@sl
P214
P106
P214
P2456
P31
P496
0000-0003-3031-3377
P7859
viaf-100423839